What's The Catalyst Driving CPRX?

(RTTNews) - Catalyst Pharmaceuticals Inc. (CPRX) has reported encouraging results from an investigator-sponsored trial evaluating its investigational drug candidate Firdapse as a treatment for myasthenia gravis patients with anti-MuSK antibodies.

Myasthenia gravis with antibodies against the muscle-specific tyrosine kinase (MuSK abs) is an ultra-rare sub-population of myasthenia gravis patients which is a debilitating neuromuscular disease, and there are currently no FDA approved therapies for this specific form of myasthenia gravis.

In the seven patient investigator-sponsored trial, both the co-primary efficacy endpoints of change from baseline in total Quantitative Myasthenia Gravis score and change from baseline in total Myasthenia Gravis Activities of Daily Living were statistically and clinically significant.

Armed with positive data, the Company now intends to proceed to U.S. multi-center pivotal trial.

The company is slated to release fourth-quarter and year-end 2016 financial results after market close on Wednesday, March 15, 2017.

CPRX is currently trading at $1.38, up 17.68%.